API
< Back to all clusters
[HEALTH] · Brazil, United States, Germany · 103 sources (showing 100)

started · updated

Brazil advances HIV prevention and reports 13 remission cases at AIDS conference

Scientists announced two additional HIV remission cases at the 26th International AIDS Conference in Rio de Janeiro, raising the worldwide total to 13. The patients – one from Kansas City, USA, and another from Essen, Germany – received hematopoietic stem‑cell transplants from donors carrying the CCR5‑delta32 mutation, which blocks HIV entry. After stopping antiretroviral therapy, the Kansas City patient has remained virus‑free for 14 months and the Essen patient for 12 months, though the latter experienced a hepatitis B recurrence.

Brazil's Ministry of Health also signed several agreements on new HIV‑prevention drugs. A memorandum of understanding between Fundação Oswaldo Cruz (Fiocruz) and MSD will enable production of the oral PrEP candidate Alimatravir (MK‑8527), pending phase‑3 trial results and ANVISA approval. The ministry announced a deal with ViiV Healthcare for the injectable PrEP cabotegravir, which will be evaluated by Conitec for possible inclusion in the SUS by the end of the year. Negotiations for the six‑month injectable lenacapavir failed because the price offered by Gilead was deemed unaffordable, even though Brazil was prepared to pay up to ten times the price offered to similar‑income countries.

In a separate initiative, the AIDS Healthcare Foundation and the Pan‑American Health Organization (OPS) signed a collaboration to expand HIV testing and early treatment access across Latin America and the Caribbean.

Entities

Alexandre Padilha · Alimatravir (MK‑8527) · Brazil Ministry of Health · Brazil Ministry of Health (Alexandre Padilha) · Brazilian Ministry of Health · Cabotegravir · Fiocruz (Fundação Oswaldo Cruz) · Fundação Oswaldo Cruz (Fiocruz) · GSK · Kansas City patient · MSD (Merck Sharp & Dohme) · SUS

Claims

What the coverage asserts, and how many sources carry each claim.

Sources